Unraveling predictors affecting compliance to MRI in Parkinson's disease.

Cacciari C, Pellicano C, Cravello L, Assogna F, Piras F, Paravia P, Gili T, Iorio M, Stefani A, Pierantozzi M, Caltagirone C, Pontieri FE, Spalletta G.

Parkinsonism Relat Disord. 2015 Aug;21(8):964-7. doi: 10.1016/j.parkreldis.2015.05.009.

Loss of angiotensin II receptor expression in dopamine neurons in Parkinson's disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation.

Zawada WM, Mrak RE, Biedermann J, Palmer QD, Gentleman SM, Aboud O, Griffin WS.

Acta Neuropathol Commun. 2015 Feb 3;3:9. doi: 10.1186/s40478-015-0189-z.

Constant Current versus Constant Voltage Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease.

Ramirez de Noriega F, Eitan R, Marmor O, Lavi A, Linetzky E, Bergman H, Israel Z.

Stereotact Funct Neurosurg. 2015 Feb 18;93(2):114-121. [Epub ahead of print]

Restless legs syndrome and hypothyroidism.

Rodríguez Martín C, Miranda Riaño S, Celorrio San Miguel M, Prieto de Paula JM.

Rev Clin Esp. 2015 May;215(4):247-9. doi: 10.1016/j.rce.2014.12.007. English, Spanish. No abstract available.

Overexpression of cystathionine γ-lyase suppresses detrimental effects of spinocerebellar ataxia type 3.

Snijder PM, Baratashvili M, Grzeschik NA, Leuvenink HG, Kuijpers L, Huitema S, Schaap O, Giepmans BN, Kuipers J, Miljkovic JL, Mitrovic A, Bos EM, Szabó C, Kampinga HH, Dijkers PF, Den Dunnen WF, Fili

Mol Med. 2015 Oct 13. doi: 10.2119/molmed.2015.00221. [Epub ahead of print]

Biomechanical analysis of spasticity treatment in patients with multiple sclerosis.

Wininger M, Craelius W, Settle J, Robinson S, Isaac B, Maloni H, Moradi M, Newby NA, Wallin M.

Ther Adv Neurol Disord. 2015 Sep;8(5):203-11. doi: 10.1177/1756285615601390.

Lack of enzyme activity in GBA2 mutants associated with hereditary spastic paraplegia/cerebellar ataxia (SPG46).

Sultana S, Reichbauer J, Schüle R, Mochel F, Synofzik M, van der Spoel AC.

Biochem Biophys Res Commun. 2015 Sep 11;465(1):35-40. doi: 10.1016/j.bbrc.2015.07.112.

Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson's disease.

Wang M, Zhu J, Pan Y, Dong J, Zhang L, Zhang X, Zhang L.

J Neurosci Res. 2015 Mar;93(3):487-94. doi: 10.1002/jnr.23504.

Dystonia and cerebellar degeneration in the leaner mouse mutant.

Raike RS, Hess EJ, Jinnah HA.

Brain Res. 2015 Jun 22;1611:56-64. doi: 10.1016/j.brainres.2015.03.011.

Perinatal 6-Hydroxydopamine to Produce a Lifelong Model of Severe Parkinson's Disease.

Kostrzewa JP, Kostrzewa RA, Kostrzewa RM, Brus R, Nowak P.

Curr Top Behav Neurosci. 2015 Oct 17. [Epub ahead of print]

Two novel mutations of the SETX gene and ataxia with oculomotor apraxia type 2.

Pera J, Lechner S, Biskup S, Strach M, Grodzicki T, Slowik A.

Clin Neurol Neurosurg. 2015 Jan;128:44-6. doi: 10.1016/j.clineuro.2014.10.024. No abstract available.

Dietary factors in the etiology of Parkinson's disease.

Agim ZS, Cannon JR.

Biomed Res Int. 2015;2015:672838. doi: 10.1155/2015/672838. Review.

Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study.

Seraji-Bozorgzad N, Bao F, George E, Krstevska S, Gorden V, Chorostecki J, Santiago C, Zak I, Caon C, Khan O.

Mov Disord. 2015 Sep;30(10):1400-4. doi: 10.1002/mds.26323.

[The protection of scorpion venom derived activity peptide against the change of dynorphin in the early Parkinson's disease rats].

Wang DM, Zhao D, Yin SM, An D, Chen W, Yu DQ, Xu H, Zhao J, Zhang WQ, Tian YX.

Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2015 Mar;31(2):120-2. Chinese. No abstract available.

Methylmercury can induce Parkinson's-like neurotoxicity similar to 1-methyl-4- phenylpyridinium: a genomic and proteomic analysis on MN9D dopaminergic neuron cells.

Shao Y, Figeys D, Ning Z, Mailloux R, Chan HM.

J Toxicol Sci. 2015 Dec;40(6):817-28. doi: 10.2131/jts.40.817.